GlassScriptPhysician profile
Peter W Bulik
NPI 1184987604
$2,884.30
in general payments reported to CMS, 2019-2025
24 companies · $486 in 2025
The $486 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $28.96 · 2021: $137 · 2022: $317 · 2023: $485 · 2024: $1,009 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,980.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $684.80 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $459.93 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $272.32 | 2022-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $191.38 | 2021-2024 | Symplicity G3 |
| Abbott Laboratories | $164.58 | 2019 | |
| W. L. Gore & Associates, INC. | $134.83 | 2022 | |
| American Regent | $129.41 | 2024-2025 | Injectafer |
| Novartis Pharmaceuticals Corporation | $121.76 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.55 | 2023-2025 | Jardiance |
| Amgen INC. | $93.73 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $84.40 | 2020-2024 | |
| Medtronic Vascular, INC. | $56.52 | 2019 | |
| Edwards Lifesciences Corporation | $49.42 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $48.26 | 2024-2025 | Farxiga |
| Novo Nordisk INC | $46.29 | 2025 | Wegovy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $45.11 | 2022-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $40.00 | 2025 | |
| Boston Scientific Corporation | $35.58 | 2019-2021 | |
| Impulse Dynamics (USA) INC. | $32.14 | 2025 | Optimizer |
| Heartflow, INC. | $22.83 | 2025 | |
| Abiomed | $19.98 | 2025 | |
| Kestra Medical Technology Services, INC. | $18.33 | 2023 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $16.85 | 2025 | Uptravi, Opsumit |
| Janssen Pharmaceuticals, INC | $15.30 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Bulik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.